REDDING,
Calif., May 23, 2024 /PRNewswire/ -- According to
a new market research report titled, 'Continuous Bioprocessing
Market by Product (Filtration, Chromatography,
Bioreactor, Incubator, Centrifuge, Reagents) Process (Upstream,
Downstream) Application (Monoclonal Antibodies, Vaccines, Plasma
Fractionation, R&D) End User—Global Forecast to 2031",
published by Meticulous Research®, the continuous
bioprocessing market is projected to reach $1.32 billion by 2031 at a CAGR of 19.6% from
2024 to 2031.
Download Sample Report Now-
https://www.meticulousresearch.com/download-sample-report/cp_id=5079
Continuous bioprocessing has become a major trend in
biopharmaceutical manufacturing due to its agility, flexibility,
efficiency, and robustness. It reduces the number of steps and
holds, requires smaller facilities with limited equipment, and
improves product quality, enabling real-time release. Advantages
such as cost efficiency and improved product quality are expected
to drive the adoption of continuous bioprocessing in the
biopharmaceutical industry in the coming years. Continuous
bioprocessing involves the use of filtration, chromatography,
centrifugation, bioreactors, incubators/shakers, sterilizers, cell
culture media, buffers, and reagents.
Bioprocessing 4.0 Generating Growth Opportunities for Market
Stakeholders
Bioprocessing 4.0 is defined as an end-to-end connected
bioprocess, where all equipment and systems in the process are
connected digitally, forming the Industrial Internet of Things
(IIoT) to run, control, and enhance the process through feedback
loops and Machine Learning (ML) or Artificial Intelligence
(AI).
The rapid development in emerging economies, progressing
research on biologics, and the increasing penetration of
biopharmaceuticals have created tremendous opportunities for
biopharma manufacturers, boosting the demand for continuous
bioprocessing technologies. The manufacture of biologics has grown
significantly over the last five years. The industry is shifting
towards Bioprocessing 4.0, a term derived from Industry 4.0, a
national strategic initiative launched by the German government in
2010. The Biopharma 4.0 concept has steadily gained momentum over
the past several years, generating market growth opportunities.
Bioprocessing 4.0 integrates automation technologies such as
robotics, big data analytics, artificial intelligence, and machine
learning, among others, to improve bioprocesses in the
pharmaceutical industry. AI-driven predictive analytics and
modeling help in biopharmaceutical process development, reducing
costs, time, and risks associated with experiment-based approaches.
Biopharmaceutical manufacturers are under constant pressure to
develop biopharmaceuticals in shorter timeframes without
compromising product safety and quality, driving the demand for
Bioprocessing 4.0.
Get a Glimpse Inside: Request Sample Pages-
https://www.meticulousresearch.com/request-sample-report/cp_id=5079
The key players operating in the continuous bioprocessing market
are 3M Company (U.S.), Thermo Fisher
Scientific, Inc. (U.S.), Sartorius AG (Germany), Eppendorf AG (Germany), Danaher Corporation (U.S.), Merck
KGaA (Germany), Repligen
Corporation (U.S.), Getinge AB (Sweden), Bionet (Spain), Corning Incorporated (U.S.), Fujifilm
Holdings Corporation (Japan),
Entegris, Inc. (U.S.), and Meissner Corporation (U.S.).
Among all the products studied in this report,
the filtration systems & consumables segment is expected
to register the highest CAGR during the forecast period. The high
growth of this segment is driven by the high preference for
filtration methods as a separation technique in bioprocessing,
technological advancements in filtration devices, and the need for
high cell densities in controlling the bioburden in
biopharmaceuticals. Investments by market players in advancing
filtration systems also support the growth of this segment. For
instance, in May 2023, 3M Company (U.S.) invested $150 million in advancing its biopharma
filtration technology. The investment includes facility and
equipment improvements in 3M
manufacturing facilities in Europe.
Among all the process types studied in this report, in 2024,
the downstream processes segment is expected to account for
the larger share of the continuous bioprocessing market. The
segment's large share is attributed to the high adoption of
downstream processing in continuous manufacturing to check the
final product quality, the increasing use of downstream
bioprocessing for vaccine production and viral inactivation, and
the increasing number of CMOs engaged in downstream processing. The
players in this market are focused on strategic collaborations to
advance downstream processes. For instance, in January 2023, Sartorius AG (Germany) collaborated with RoosterBio, Inc.
(U.S.) to advance downstream purification processes in exosome
manufacturing.
Have Specific Research Needs? Request a Customized
Report-
https://www.meticulousresearch.com/request-customization/cp_id=5079
Among all the applications studied in this report, in 2024,
the commercial applications segment is expected to account for
the larger share of the continuous bioprocessing market. Increasing
investments in constructing facilities compatible with continuous
bioprocessing for the commercial manufacture of biopharmaceuticals
is a key factor supporting this segment's large share. The
implementation of continuous bioprocessing in commercial
biopharmaceutical manufacturing improves productivity and reduces
manufacturing costs, reducing the prices of biopharmaceutical
products, making medicines more accessible, and improving the
quality of care. The shift in focus toward personalized medicines
and individualized biologics also supports the adoption of
continuous biomanufacturing in commercial applications.
Among all the end users studied in this report, the CDMOs
& CROs segment is expected to register the highest CAGR during
the forecast period. The demand for continuous bioprocessing among
CDMOs & CROs is expected to increase during the forecast
period, mainly due to the flexibility offered by continuous
bioprocessing and rising investments and partnerships among CDMOs
and CROs. Continuous manufacturing reduces the overall process
duration, helping save on operational and utility costs. These
benefits are expected to support the adoption of continuous
bioprocessing among CDMOs & CROs, boosting the growth of this
segment.
Geographically, in 2024, North
America is expected to account for the largest share of the
continuous bioprocessing market. North
America's major market share is attributed to the high
R&D expenditure, growth in the pharmaceutical industry, and
increasing pharmaceutical expenditure in the region. Also,
initiatives supporting the uptake of biosimilars, and the rising
number of biopharmaceutical approvals are accelerating research on
precision medicines. According to the U.S. FDA, in 2023, 25
biologics were approved, compared to 14 in 2022.
Browse In-depth Report Now-
https://www.meticulousresearch.com/product/continuous-bioprocessing-market-5079
Scope of the Report:
Continuous Bioprocessing Market Assessment—by
Product
- Filtration Systems & Consumables
- Chromatography Systems & Consumables
- Cell Culture Media, Buffers, and Reagents
- Incubators & Shakers
- Bioreactors
- Centrifuges
- Sterilizers
- Other Instruments & Consumables
Note: Other instruments & consumables include
membrane absorbers, connectors & clamps, and sampling
systems.
Continuous Bioprocessing Market Assessment—by
Process Type
- Upstream Processes
- Downstream Processes
Continuous Bioprocessing Market Assessment—by
Application
- Commercial Applications
- Monoclonal Antibodies (mAb) Production
- Cell & Gene Therapy Production
- Vaccine Manufacturing
- Plasma Fractionation
- Recombinant Protein Production
- Research & Development (R&D) Applications
Continuous Bioprocessing Market Assessment—by
End User
- Pharmaceutical & Biotechnology Companies
- Contract Development & Manufacturing Organizations (CDMOs)
& Contract Research Organizations (CROs)
- Academic & Research Institutes
Continuous Bioprocessing Market Assessment—by
Geography
- North America
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Ireland
- Denmark
- Belgium
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific
(RoAPAC)
- Latin America
- Middle East & Africa
Unlock Opportunities: Buy Now-
https://www.meticulousresearch.com/Checkout/13717155
Related Reports:
Biopharmaceutical Processing Equipment and Consumables Market by
Product Type (Filtration, Chromatography [Consumables, Equipment],
Disposable Bioreactors, Cell Culture Media, Shakers, Services),
Application (Vaccine, mAb, R&D), and End User- Forecast to
2029
Antibody Production Market by Product [Bioreactors (Single-use,
Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers,
Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit],
Process [Downstream, Upstream] – Global Forecast to 2031
Single-use Bioreactors Market by Product [Systems, Media Bags
(2D, 3D), Filtration Assemblies], Type [Stirred-tank,
Wave-induced], Cell [Mammalian, Bacterial, Yeast], Application
[Commercial (mAb, Vaccine), Research], End User - Global Forecast
to 2030
Chromatography Market by Product (Systems, Columns, Reagents,
Vials, Fittings, Detectors, Pumps, Software), Technology (HPLC,
LPLC, Flash Chromatography, GC, TLC), End User (Pharmaceutical,
Academic, F&B, Environmental, Hospital) – Global Forecast to
2030
Cell Culture Market by Product [Consumables (Media, Reagents,
Sera, Cell Lines), Equipment (Bioreactor, Centrifuge, Cell
Counter)], Application (Bioproduction, Cancer Research, Stem Cell,
Diagnostic), End User (Pharma, Academic) - Global Forecast to
2029
Related Blogs:
Top 10 Companies in Continuous Bioprocessing Market
About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as
Meticulous Market Research Pvt. Ltd. in 2013 as a private limited
company under the Companies Act, 1956. Since its incorporation, the
company has become the leading provider of premium market
intelligence in North America,
Europe, Asia-Pacific, Latin
America, and the Middle
East & Africa.
The name of our company defines our services, strengths, and
values. Since the inception, we have only thrived to research,
analyze, and present the critical market data with great attention
to details. With the meticulous primary and secondary research
techniques, we have built strong capabilities in data collection,
interpretation, and analysis of data including qualitative and
quantitative research with the finest team of analysts. We design
our meticulously analyzed intelligent and value-driven syndicate
market research reports, custom studies, quick turnaround research,
and consulting solutions to address business challenges of
sustainable growth.
Contact:
Mr. Khushal Bombe
Meticulous Market Research Inc.
1267 Willis St, Ste 200 Redding,California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn-
https://www.linkedin.com/company/meticulous-research
Content Source:
https://www.meticulousresearch.com/pressrelease/266/continuous-bioprocessing-market-2031
Logo:
https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg
View original
content:https://www.prnewswire.com/news-releases/continuous-bioprocessing-market-to-be-worth-1-32-billion-by-2031---exclusive-report-by-meticulous-research-302154187.html
SOURCE Meticulous Market Research Pvt. Ltd.